Prostate Cancer · LIVING RESEARCH LIBRARY

Ongoing Research for Prostate Cancer Using Advanced Alternative Medicine

Explore positive published findings by substance, cancer biology, treatment interaction and quality-of-life outcome.

Every entry includes the original study title, year, concise finding and a direct PubMed link.

Call 1.800.923.7878

Ask About Your Prostate Cancer Case

Tell us the diagnosis, stage, biomarkers, current treatment plan and research questions you want to understand. Our Patient Care Team will follow up personally.

Prefer to speak now?
Call 1.800.923.7878

Explore this cancer section

Prostate Cancer

Living research library · positive published findings

Research organized by substance and finding

Browse 30 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked substance to move directly to its corresponding Sunridge page.

α-lipoic acid modulates prostate cancer cell growth and bone cell differentiation.

2024 · Cancer biology and response

A nutraceutical, namely, α-lipoic acid (α-LA), is known for its potent anti-cancer properties towards various cancers and has been implicated in treating and promoting bone health.

Open study on PubMed →

Amygdalin Exerts Antitumor Activity in Taxane-Resistant Prostate Cancer Cells.

2022 · Tumor growth and proliferation

Amygdalin dose-dependently inhibited tumor growth and reduced tumor clones in all (parental and resistant) PCa cell lines, accompanied by a G0/G1 phase accumulation.

Open study on PubMed →

Amygdalin Modulates Prostate Cancer Cell Adhesion and Migration In Vitro.

2020 · Metastasis and invasion

Amygdalin significantly reduced chemotactic activity, migration, and adhesion of DU-145 but not of PC3 cells.

Open study on PubMed →

Dihydroartemisinin induces cell apoptosis through repression of UHRF1 in prostate cancer cells.

2022 · Metastasis and invasion

Our results suggested that dihydroartemisinin decreases proliferation and migration but enhances apoptosis of PCa cells, likely by downregulating UHRF1 and upregulating p16INK4A.

Open study on PubMed →

Curcumin inhibits prostate cancer by upregulating miR-483-3p and inhibiting UBE2C.

2024 · Cancer biology and response

Many evidence have shown the efficacy of curcumin (CUR) in inhibiting the progression of PCa.

Open study on PubMed →

Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p/PCLAF axis.

2021 · Metastasis and invasion

In addition, transfection of miR-30a-5p inhibitors partially reversed the function of curcumin on cell proliferation, migration, invasion and apoptosis.

Open study on PubMed →

Cytotoxicity of curcumin against CD44± prostate cancer cells: Roles of miR-383 and miR-708.

2023 · Apoptosis and cell death

We used Annexin V-FITC/PI to quantify apoptotic cell death. qRT-PCR was also used to detect miRNA and gene expression levels after curcumin treatment.

Open study on PubMed →

The Role of Curcumin in Prostate Cancer Cells and Derived Spheroids.

2022 · Apoptosis and cell death

Finally, chemotherapeutic agents and curcumin reduced the size of DU145 and PC-3 spheroids and have the potential to induce apoptosis and also in Matrigel.

Open study on PubMed →

Copper-EGCG nanoreactor orchestrates dual-metabolic assault and self-amplified cuproptosis for immunogenic prostate cancer therapy.

2026 · Metabolism and redox biology

The Cu-EQ NPs leverage the tumor microenvironment to release copper ions that trigger TCA-dependent cuproptosis, while the EGCG component simultaneously inhibits key glycolytic enzymes to prevent metabolic escape.

Open study on PubMed →

Ginsenoside Rh2 repressed the progression of prostate cancer through the mitochondrial damage induced by mitophagy and ferroptosis.

2025 · Apoptosis and cell death

Ginsenoside Rh2 (GRh2), a ginseng-derived bioactive compound, exhibits antitumor potential, but its efficacy and mechanisms in PC remain unclear.

Open study on PubMed →

Induction of apoptosis in prostate cancer by ginsenoside Rh2.

2018 · Apoptosis and cell death

In conclusion, our findings have demonstrated that ginsenoside Rh2 induces prostate cancer DU145 cells apoptosis through up-regulation of PPAR-delta expression which is associated with p-STAT3 up-regulation and ROS/superoxide induction.

Open study on PubMed →

Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer

2012 · Survival and clinical response

A small clinical series reported partial PSA responses in half of the participants and stabilization in another quarter after insulin-potentiated low-dose chemotherapy.

Open study on PubMed →

Melatonin decreases androgen-sensitive prostate cancer growth by suppressing SENP1 expression.

2022 · Metastasis and invasion

Herein, we report that melatonin has the ability to decrease the growth and metastasis of androgen-dependent prostate cancer.

Open study on PubMed →

Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression.

2021 · Metastasis and invasion

Importantly, tumor growth rate and metastasis to distant organs were suppressed by melatonin in an orthotopic prostate cancer model.

Open study on PubMed →

Targeting Melatonin to Mitochondria Mitigates Castration-Resistant Prostate Cancer by Inducing Pyroptosis.

2025 · Metabolism and redox biology

The modification of melatonin (Mel) to a triphenylphosphonium (TPP) cation-targeted mitochondria-melatonin (Mito-Mel) significantly increases its potency by over 1000-fold.

Open study on PubMed →

‌Liquid-Liquid Phase Separation of AR Orchestrated by Melatonin Sensitizes Prostate Cancer to Ferroptosis Via MCM5/NRF2 Axis Collapse.

2025 · Metastasis and invasion

We found that MEL effectively inhibited PCa proliferation, migration, and invasion in vitro while suppressing tumor growth safely in mice models.

Open study on PubMed →

Mistletoe Extracts Inhibit Progressive Growth of Prostate Cancer Cells.

2025 · Tumor growth and proliferation

All mistletoe extracts significantly inhibited cell growth in a dose-dependent manner and cell proliferation and clonogenicity were suppressed.

Open study on PubMed →

From microbes to medicine: harnessing the gut microbiota to combat prostate cancer.

2024 · Metabolism and redox biology

The microbiota can also affect drug metabolism and toxicity, which may improve the response to cancer treatment.

Open study on PubMed →

Quercetin-Resveratrol Combination for Prostate Cancer Management in TRAMP Mice.

2020 · Apoptosis and cell death

Utilizing PCa PCR array analysis with prevention tumor tissues, we identified that quercetin-resveratrol modulates genes involved in promoter methylation, cell cycle, apoptosis, fatty acid metabolism, transcription factors, androgen response, PI3K/AKT and PTEN signaling.

Open study on PubMed →

7-O-tyrosyl Silybin Derivatives as a Novel Set of Anti-Prostate Cancer Compounds.

2024 · Cancer biology and response

Silybin is a natural compound extensively studied for its hepatoprotective, neuroprotective and anticancer properties.

Open study on PubMed →

Core Structure-Activity Relationship Studies of 5,7,20-O-Trimethylsilybins in Prostate Cancer Cell Models.

2023 · Tumor growth and proliferation

Our previous studies established 5,7,20-O-trimethylsilybins as promising lead compounds as they can selectively suppress androgen receptor (AR)-positive LNCaP cell proliferation.

Open study on PubMed →

Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.

2016 · Tumor growth and proliferation

The WST-1 cell proliferation assay indicates that nineteen out of twenty-four silibinin derivatives have significantly improved antiproliferative potency when compared with silibinin.

Open study on PubMed →

Silibinin Radiosensitizes EGF Receptor-knockdown Prostate Cancer Cells by Attenuating DNA Repair Pathways.

2022 · Treatment response

The pro-survival signaling proteins, phospho-extracellular signal-regulated kinases (ERK)1/2, phospho-Akt and phospho-STAT3 were decreased by silibinin in EGFR-deficient PCa cells.

Open study on PubMed →

Effects of sulforaphane on prostate cancer stem cells-like properties: In vitro and molecular docking studies.

2024 · Apoptosis and cell death

Furthermore, the verification experiments showed that the activators of Wnt/β-catenin (LiCl) and hedgehog (purmorphamine) attenuated the effects of SFN on PCSCs, including the expression of stem cell markers, cell proliferation and apoptosis.

Open study on PubMed →

Sulforaphane inhibits the growth of prostate cancer by regulating the microRNA-3919/DJ-1 axis.

2024 · Cancer biology and response

Sulforaphane (SFN), an isothiocyanate compound, has been shown to exert inhibitory effects on a variety of cancers.

Open study on PubMed →

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.

2026 · Treatment response

The use of ascorbate, more commonly known as ascorbic acid or Vitamin C, has demonstrated antitumor activity in a variety of cancer cell types.

Open study on PubMed →

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.

2023 · Treatment response

There are several mechanisms currently under investigation to explain how ascorbate exerts anti-cancer effects.

Open study on PubMed →

Ferroptosis induction, androgen biosynthesis disruption and prostate cancer suppression by androgen and vitamin D combination.

2025 · Metastasis and invasion

We show that subnanomolar/low-nanomolar calcitriol, while non-inhibitory on its own, inhibited CRPC cells upon co-treatment with androgen (5α-DHT) at a physiologic level, evident from G1/S cell cycle arrest, induction of p21/Cip1, blockade of clonal cell growth, retardation of proliferation, migration and invasion of cells in vitro, and xenograft growth suppression in vivo.

Open study on PubMed →

High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD).

2026 · Cancer biology and response

The ProsD trial aimed to determine if oral vitamin D supplementation could prevent prostate cancer (PC) progression in men on active surveillance (AS).

Open study on PubMed →

Scottsdale Clinic

14200 N Northsight Blvd #160
Scottsdale, Arizona 85260

Office Hours

Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM

Visit Sunridge in Scottsdale

FREE INTRODUCTORY CALL

Speak With Our Patient Care Team

Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.

Call Now: 1-800-923-7878

This introductory call is not a medical consultation and does not establish a physician-patient relationship.

Have a Question or Share Feedback:
It's easy to get in touch with us